PMID- 37525281
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230803
IS  - 2055-0294 (Print)
IS  - 2055-0294 (Electronic)
IS  - 2055-0294 (Linking)
VI  - 9
IP  - 1
DP  - 2023 Aug 1
TI  - Olanzapine treatment effectively relieves breakthrough chemotherapy-induced 
      nausea and vomiting: a real-world experience.
PG  - 24
LID - 10.1186/s40780-023-00293-y [doi]
LID - 24
AB  - BACKGROUND: Olanzapine treatment prevents chemotherapy-induced nausea and 
      vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). 
      However, its role in the secondary prevention of breakthrough CINV in real-world 
      cancer care should be further evaluated. METHOD: We conducted a retrospective 
      study on patients receiving olanzapine to prevent breakthrough CINV refractory to 
      standard antiemetic therapy. The major outcome was improvement in CINV, defined 
      as any downgrade in CINV symptoms, according to the Common Terminology Criteria 
      for Adverse Events. Comprete response was defined as no symptoms in CINV, i.e., 
      Grade 0. These outcomes were compared in the HEC versus non-HEC groups and the 
      standard- (5 or 10 mg/day) versus low- (2.5 mg/day) dose groups. The other 
      outcome measurement was adverse events (AEs). RESULTS: We analyzed 127 patients, 
      including 92 women, with a median age of 50 years (range: 19-89 years). Baseline 
      CINV severity was grade 1, 2, and 3 in 18%, 69%, and 13% of the patients, 
      respectively. After prophylaxis with olanzapine at doses of 2.5, 5, or 10 mg/day, 
      improvement was observed in 105 (83%) patients, with a complete response in 42 
      patients (33%). The improvement and complete remission rates for the HEC (n = 96) 
      and non-HEC (n = 31) groups were 86% and 71% (p = 0.048) versus 38% and 19% 
      (p = 0.062), respectively. The rates for the standard- (n = 98) and low- (n = 29) 
      dose groups were 86% and 82% (p = 0.568) versus 28% and 52% (p = 0.015), 
      respectively. Thirty-four patients (27%) experienced olanzapine-related AEs, 
      mainly somnolence (n = 28). Grade 3 or higher AEs were not observed. CONCLUSION: 
      Our study results support the clinical application of olanzapine for the 
      secondary prevention of breakthrough CINV.
CI  - (c) 2023. The Author(s).
FAU - Uchiike, Akihiro
AU  - Uchiike A
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan.
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
AD  - Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon 
      University, Chiba, Japan.
FAU - Kono, Haruka
AU  - Kono H
AD  - Division of Hematology and Rheumatology, Department of Medicine, Nihon University 
      School of Medicine, Tokyo, Japan.
AD  - Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
FAU - Miura, Katsuhiro
AU  - Miura K
AUID- ORCID: 0000-0002-1538-3804
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan. miura.katsuhiro@nihon-u.ac.jp.
AD  - Division of Hematology and Rheumatology, Department of Medicine, Nihon University 
      School of Medicine, Tokyo, Japan. miura.katsuhiro@nihon-u.ac.jp.
FAU - Hayama, Tatsuya
AU  - Hayama T
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan.
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Tsutsumi, Daisuke
AU  - Tsutsumi D
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan.
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Tsuboi, Shinya
AU  - Tsuboi S
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan.
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Ohtsuka, Susumu
AU  - Ohtsuka S
AD  - Nihon University Itabashi Hospital Tumor Center, 30-1 Oyaguchikamicho, Itabashi, 
      173-8610, Tokyo, Japan.
AD  - Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, Japan.
FAU - Hidaka, Shinji
AU  - Hidaka S
AD  - Department of Pharmaceutical Regulatory Science, School of Pharmacy, Nihon 
      University, Chiba, Japan.
LA  - eng
GR  - no identifier available/Daiichi-Sankyo/
PT  - Journal Article
DEP - 20230801
PL  - England
TA  - J Pharm Health Care Sci
JT  - Journal of pharmaceutical health care and sciences
JID - 101672177
PMC - PMC10391758
OTO - NOTNLM
OT  - Chemotherapy-induced nausea
OT  - Highly emetogenic chemotherapy
OT  - Olanzapine
COIS- Katsuhiro Miura received a scholarship donation from Daiichi-Sankyo. The other 
      authors have no conflicts of interest to declare.
EDAT- 2023/08/01 01:08
MHDA- 2023/08/01 01:09
PMCR- 2023/08/01
CRDT- 2023/07/31 23:48
PHST- 2023/04/18 00:00 [received]
PHST- 2023/06/08 00:00 [accepted]
PHST- 2023/08/01 01:09 [medline]
PHST- 2023/08/01 01:08 [pubmed]
PHST- 2023/07/31 23:48 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - 10.1186/s40780-023-00293-y [pii]
AID - 293 [pii]
AID - 10.1186/s40780-023-00293-y [doi]
PST - epublish
SO  - J Pharm Health Care Sci. 2023 Aug 1;9(1):24. doi: 10.1186/s40780-023-00293-y.